DUARTE, Calif., Aug. 18, 2017 /PRNewswire/ -- Prolacta Bioscience, the nation's leading provider of human milk-based neonatal nutritional products to hospitals, has released several new resources for nurses and clinicians working with premature infants in the neonatal intensive care unit (NICU).
Webinar on Multi-Study Review of the Use of Human Milk-Derived Cream and Outcomes
Prolacta's Nutrition Advisory Committee (NAC) held a webinar on Wednesday, Aug. 16, on the "Multi-Study Review of The Use of Human Milk-Derived Cream in Very Low Birth Weight Infants and Outcomes."
The webinar focused on two articles on the use of Prolacta's human milk-derived cream to improve overall caloric intake without substantially altering the volume infants are fed.
Webinar on Transitioning a NICU to an EHMD
A third webinar will be available on Wednesday, Sept. 20.
The webinar, titled: "Successfully Implementing an Exclusive Human Milk Diet in the NICU: A Nurse Director's Insights and Lessons Learned," will explain how hospitals can ease the transition to an EHMD into their NICUs.
When used as part of an EHMD, Prolacta's neonatal nutritional products are clinically proven to improve health outcomes2,3,4 and reduce hospital costs5,6 for critically ill, extremely premature infants weighing between 500-1,250g (1 lb 1 oz to 2 lbs 12 oz) at birth, in the NICU, as compared to cow milk-based fortifier or cow milk-based preterm formula.
About Prolacta Bioscience Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based neonatal nutritional products to meet the needs of critically ill, premature infants in the NICU. Prolacta leads the industry in the quality and safety of nutritional products made from donor breast milk and operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk.